从一名接受利妥昔单抗治疗的CD20阳性弥漫性大B细胞淋巴瘤患者中建立一种新型CD20阴性成熟B细胞系WILL2。 - Suppr

Establishment of a novel CD20 negative mature B-cell line, WILL2, from a CD20 positive diffuse large B-cell lymphoma patient treated with rituximab.

作者信息

Sonoki Takashi, Li Yaqiong, Miyanishi Setsuko, Nakamine Hirokazu, Hanaoka Nobuyoshi, Matsuoka Hiroshi, Mori Ichiro, Nakakuma Hideki

机构信息

Department of Hematology/Oncology, Wakayama Medical University, 811-1 Kimi-idera, Wakayama, 633-1611, Japan.

2nd Department of Pathology, Wakayama Medical University, Wakayama, Japan.

出版信息

Int J Hematol. 2009 Apr;89(3):400-402. doi: 10.1007/s12185-009-0295-4. Epub 2009 Mar 31.

DOI:10.1007/s12185-009-0295-4

PMID:19330555

Abstract

摘要

相似文献

Establishment of a novel CD20 negative mature B-cell line, WILL2, from a CD20 positive diffuse large B-cell lymphoma patient treated with rituximab.

Int J Hematol. 2009 Apr;89(3):400-402. doi: 10.1007/s12185-009-0295-4. Epub 2009 Mar 31.

Waxing and waning intravascular large cell lymphoma with widespread organ infiltration.

Leuk Lymphoma. 2011 Apr;52(4):705-8. doi: 10.3109/10428194.2010.543713. Epub 2010 Dec 29.

Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.

Cancer Biother Radiopharm. 2004 Oct;19(5):545-61. doi: 10.1089/cbr.2004.19.545.

De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: molecular mechanisms and correlation with rituximab sensitivity.

Cancer Sci. 2014 Jan;105(1):35-43. doi: 10.1111/cas.12307. Epub 2013 Dec 22.

Anti-CD20 monoclonal antibody (Rituximab) for therapy of mediastinal CD20-positive large B-cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl.

Pediatr Hematol Oncol. 2003 Jun;20(4):339-44. doi: 10.1080/08880010390203125.

CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure.

Haematologica. 2009 Mar;94(3):423-7. doi: 10.3324/haematol.2008.001024. Epub 2009 Feb 11.

[Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].

Rinsho Ketsueki. 2004 Oct;45(10):1129-34.

Peripheral T-cell lymphoma following rituximab therapy for B-cell lymphoma.

Blood. 1999 Apr 1;93(7):2427-8.

CD5-positive diffuse large B-cell lymphoma with an unusual phenotype: Cytoplasmic CD20 (+), surface CD20 (-).

Leuk Lymphoma. 2006 Jul;47(7):1415-7. doi: 10.1080/10428190600581625.

Diffuse large B-cell lymphoma on the back of a patient with AIDS: successful treatment by the CD20 monoclonal antibody rituximab.

Int J Dermatol. 2005 Nov;44(11):976-8. doi: 10.1111/j.1365-4632.2005.02649.x.

引用本文的文献

Expanding anti-CD38 immunotherapy for lymphoid malignancies.

J Exp Clin Cancer Res. 2022 Jun 28;41(1):210. doi: 10.1186/s13046-022-02421-2.

Allogeneic CD20-targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma models.

Clin Transl Immunology. 2022 Feb 2;11(2):e1373. doi: 10.1002/cti2.1373. eCollection 2022.

Differential gene expression profiling linked to tumor progression of splenic marginal zone lymphoma.

Sci Rep. 2017 Sep 8;7(1):11026. doi: 10.1038/s41598-017-11389-5.

Genetic and Epigenetic Modulation of CD20 Expression in B-Cell Malignancies: Molecular Mechanisms and Significance to Rituximab Resistance.

J Clin Exp Hematop. 2016;56(2):89-99. doi: 10.3960/jslrt.56.89.

De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: molecular mechanisms and correlation with rituximab sensitivity.

Cancer Sci. 2014 Jan;105(1):35-43. doi: 10.1111/cas.12307. Epub 2013 Dec 22.

Loss of CD20 antigen expression after rituximab therapy of CD20 positive B cell lymphoma (diffuse large B cell extranodal marginal zone lymphoma combination): a case report and review of the literature.

Med Oncol. 2012 Jun;29(2):1223-6. doi: 10.1007/s12032-011-9955-3. Epub 2011 Jul 31.

Eradication of melanomas by targeted elimination of a minor subset of tumor cells.

Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2474-9. doi: 10.1073/pnas.1009069108. Epub 2011 Jan 31.

本文引用的文献

Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma.

N Engl J Med. 2008 Aug 7;359(6):613-26. doi: 10.1056/NEJMra0708875.

Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy.

Int J Hematol. 2007 Jul;86(1):49-57. doi: 10.1532/IJH97.07028.

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.

Oncogene. 2003 Oct 20;22(47):7359-68. doi: 10.1038/sj.onc.1206939.

CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.

Ann Hematol. 2003 Sep;82(9):585-8. doi: 10.1007/s00277-003-0694-1. Epub 2003 Jul 31.

Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.

Clin Cancer Res. 1999 Mar;5(3):611-5.

CD20-negative relapse in B-cell lymphoma after treatment with Rituximab.

J Clin Oncol. 1998 Dec;16(12):3916.

Thermostable DNA polymerase chain amplification of t(14;18) chromosome breakpoints and detection of minimal residual disease.

Proc Natl Acad Sci U S A. 1988 Jul;85(13):4869-73. doi: 10.1073/pnas.85.13.4869.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Establishment of a novel CD20 negative mature B-cell line, WILL2, from a CD20 positive diffuse large B-cell lymphoma patient treated with rituximab.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献